ClinConnect ClinConnect Logo
Search / Trial NCT06887543

The Impact of Time Restricted Eating on Type 2 Diabetes

Launched by ROCKEFELLER UNIVERSITY · Mar 19, 2025

Trial Information

Current as of April 29, 2025

Not yet recruiting

Keywords

Type 2 Diabetes Time Restricted Eating Intermittent Fasting

ClinConnect Summary

The EaT2D Study is a clinical trial investigating how the timing of meals affects people with type 2 diabetes. Specifically, it looks at "time-restricted eating," which means having all your meals within a set period during the day and fasting for the rest. In this study, participants will either eat most of their calories before 2 PM or follow their usual eating habits, which often include eating later in the day. The goal is to see how these different eating patterns impact blood sugar levels, weight, and other health markers.

To participate, individuals must be between 18 and 75 years old, have a body mass index (BMI) over 25, and have a specific blood sugar level. Participants should be willing to eat only the food provided by the study and follow a strict eating schedule for six days. This research aims to explore whether eating earlier in the day can help improve health outcomes for those with diabetes, potentially leading to better blood sugar control and weight management.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Age 18-75 able to give consent
  • 2. BMI \>25 kg/m2
  • 3. Hemoglobin A1C ≥ 6.5%
  • 4. Willing to eat only the food provided
  • 5. Willing to follow the feeding schedule, including fasting for 16 hours/day for six days.
  • 6. Usual sleep time is between 10 PM and 8 AM
  • 7. Fluent in the English language
  • Exclusion Criteria:
  • 1. Current use of anti-obesity medications (Ozempic, Mounjaro, Trulicity, Wegovy, Zepbound, Qsymia, Contrave, Saxenda, Victoza, Orlistat)
  • 2. Report history of Cirrhosis
  • 3. HIV positive
  • 4. Self-reported autoimmune disease (rheumatoid arthritis, systemic lupus erythematosus, Crohn's disease, ulcerative colitis, psoriasis, etc.)
  • 5. Current use of steroids (inhalers are permissible)
  • 6. Currently pregnant
  • 7. Smoked tobacco within the last 3 months
  • 8. Allergy to adhesive tape
  • 9. Skips breakfast
  • 10. Followed TRF or intermittent fasting in the last 2 weeks
  • 11. Shift or night worker
  • 12. Current use of insulin
  • 13. Current use of sulfonylureas
  • 14. Current use of glucagon-like peptide-1 (GLP-1) receptor agonists
  • 15. Hemoglobin A1c \>8%
  • 16. Unable to sync smartphone with Bluetooth for scale data
  • 17. Any medical, psychological, or social condition that, in the opinion of the investigator, would jeopardize the health or well-being of the participant during any study procedures or the integrity of the data.

About Rockefeller University

Rockefeller University is a leading biomedical research institution dedicated to advancing the frontiers of science and medicine. Renowned for its innovative research and commitment to understanding the underlying mechanisms of health and disease, the university fosters a collaborative environment that brings together scientists from diverse fields. As a clinical trial sponsor, Rockefeller University emphasizes rigorous scientific methodology and ethical standards, aiming to translate groundbreaking discoveries into effective therapeutic interventions. With a focus on transformative research, the university plays a crucial role in shaping the future of healthcare through its robust clinical trials and commitment to improving patient outcomes.

Locations

New York, New York, United States

Patients applied

0 patients applied

Trial Officials

Jose Aleman, MD, PhD

Principal Investigator

The Rockefeller University Hospital

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported